版本:
中国

BRIEF-Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial

May 4 Oncomed Pharmaceuticals Inc:

* Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial

* Oncomed Pharmaceuticals Inc - trial will be conducted at five centers in U.S. And is expected to enroll approximately 30 patients. Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐